SYMBIOTEC

September 21, 2026

To,
The Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip code: 544889

To,
The Listing Department
National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Symbol: SYMBIOTEC

Sub: Investor Presentation - Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("SEBI Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, please find enclosed Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.

The aforesaid disclosure is also available on the Company's website at https://www.symbiotec.com/

This is for your Information and Records.

Thanking you,

For Symbiotec Pharmalab Limited

SALIL JAIN Digitally signed by SALIL JAIN Date: 2026.09.21 19:40:01 +05'30'

Salil Jain
Company Secretary & Compliance Officer

Registered Office & Works:
Symbiotec Pharmalab Limited
(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)
385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India
Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,
Email ID : symbiotec@symbiotec.com, **Website** : www.symbiotec.com
CIN: U24232MP2002PLC015293

Symbiotec Pharmalab Limited

Q1FY27 Investor Presentation

September 2026

SYMBIOTEC

Disclaimer

SYMBIOTEC

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Symbiotic Pharmalab Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

IPO & Market Debut : A New Chapter. A Significant Milestone.

Details of IPO

- ✓ Listing of Symbiotec Pharmalab Limited in September 2026
- ✓ Listing done on BSE & NSE
- ✓ IPO Price : Rs. 988 per share
- ✓ Issue Size: Rs. 1,757 Cr
  - Fresh Issue: Rs. 150 Cr
  - Offer for Sale: Rs. 1,607 Cr
- ✓ Objects of the Issue: Proceeds of Rs. 150 crores to repay or prepayment in full or part of borrowings availed by our Company

Symbiotec Pharmalab Limited listed on BSE & NSE on 1st September 2026

Q1FY27 Performance Highlights

Q1FY27 Key Business Updates

SYMBIOTEC

APIs Products

- ✓ **Sales growth steady at 6% in Q1**
  - Growth further expected to pick up in subsequent quarters
- ✓ **Successfully completed 4 major regulatory audits recently:**
  - EUGMP audits in Rau and Pithampur plants in Mar 2026
    - Approval certification received for both plants
  - USFDA audit in Mar-Apr 2026 at Rau plant – EIR received
  - USFDA audit in Aug 2026 at Pithampur plant – EIR awaited

Complex Injectables

- ✓ **Licensing agreement for distribution of two DCV products in US**
  - Term-sheet signed, Agreement at advanced stage, expected to sign off shortly
- ✓ **Successfully filed first molecule ANDA for DCV in September 2026**
  - First generic filing for the DCV product in US market
- ✓ ***Filing of second ANDA scheduled for Q4 FY27***

Biotech - CDMO Services

- ✓ **Industrial Biotech :**
  - **Customers** on-boarded
  - 10 years take-or-pay agreement with US based Alternate Protein player in place
  - 10 years take-or-pay term-sheet with Europe based Alternate Protein player in place, agreement in advanced stage
- ✓ **Bio-Pharmaceutical : Insulin Drug Substance (DS)**
  - 5 year Take or Pay agreement in place, Capex on track ; filing regulatory approval in Q4 FY27

Q1 FY27 Financials Highlights

Steady API growth offset by expenses from non-revenue generating New Bizs

Consol Revenue (Rs. in Crs)



Consol EBITDA (Rs. in Crs)



Consol PAT (Rs. in Crs)



- Drag of expenses from new businesses not yet generating revenues
  - Opex - **Rs. 23 crs**
  - Depreciation - **Rs. 12 crs**
- Revenue generation from various new businesses to commence **in next 6-12 months**

API Revenue (Rs. in Crs)



API EBITDA (Rs. in Crs)



API Profitability Maintained

- API **Gross margins upwards of 60%** across all quarters
- API **EBIDTA margins steady at ~30%** driven by revenue growth and favourable sales mix

Margins

₹ 1,000+ Crs capex invested in New Businesses

SYMBIOTEC

Revenue to commence in the next 6–12 months

₹ 1,475 Crs
Gross Capex
(as on 30th June 2026)

₹ 1,666 Crs
Total Gross Capex
(est end FY27)

39%
Share of Total Gross Capex currently generating revenue

61%
Share of Gross Capex in New Projects yet to Generate Revenues

Project / Product	Commercial Status	Gross Capex (as on 30th Jun 2026)	Total Gross Capex (est by end of FY27)	Share of Total Gross Capex	Remarks
Existing Business					
API : Steroids & Hormones	Catering to existing API revenues	644	**644**	**39%**	**Asset Turns ~1.5X**
Capex invested over years, and revenue generation in near future					
Complex Injectables : Dual Chamber Vials	Majority of capacity reserved with strategic partner	356	**376**	**61%**	**~1,000 Crs or 60% of capex to start generating revenue in 6–12 months** + **Revenue for majority of new capacities already contracted**
CDMO Services (400 kl + 14kl)	Take or pay customer arrangements for majority of capacities	471	**584**		
New API Capex	In discussions with distributors & global players	4	**63**		
Grand Total		**1,475**	**1,666**	**100%**	

NEW CDMO CAPEX
600 kl capacities to be initiated backed by customer agreement

Q1 FY27 INVESTMENT
Gross capex invested ~₹68 Cr

Management Commentary

Anil Satwani

Chairman & Managing Director

Commenting on Q1FY27 performance, Mr. Anil Satwani, Chairman & Managing Director of Symbiotec Pharmalab Limited, said:

"Our first results as a listed company reflect a business with a steady growing core and two new growth engines for the future.

The API business — built over three decades of steroid chemistry depth and regulated-market presence — delivered steady revenue growth of 6% and EBITDA growth of 9%. Consistent, cash-generative growth here is what allows us to build the new growth engines with conviction.

In Complex Injectables, we filed our first ANDA from our Dual Chamber Vial platform this quarter — one more step closer to commercialization and are progressing well towards a second filing in the coming months. Behind these filings sits a pipeline that is getting deeper: our development work is steadily adding new molecules to the DCV portfolio and opening adjacent formats, extending the platform into new therapeutic segments.

In Biotech - CDMO Services, engagement is widening steadily. New customers are exploring manufacturing programmes across our capabilities, and existing conversations are progressing favourably. This is a business built on trust and technical credibility — these innovator customers take time to build the relationship, but are very sticky delivering a highly predictable, recurring revenue stream through take-or-pay arrangements.

We have built a differentiated business at Symbiotec"

Q1FY27 Consolidated Profit & Loss Statement

SYMBIOTEC

Particular (Rs. in Crs)	Q1 FY27	Q1 FY26	Y-o-Y
Revenue from Operations	**218.2**	**203.2**	**7%**
Gross Profit	**142.6**	**125.8**	**13%**
Gross Margins (%)	**65%**	**62%**	**300 bps**
Operating Expenses - API Business	74.2	65.7	
Operating Expenses - New Businesses	**23.2**	**2.2**	
Reported EBIDTA	**45.2**	**58.0**	
Reported EBIDTA Margin (%)	**21%**	**29%**	
Depreciation & Amortization Expenses - API Business	10.2	9.3	
Depreciation & Amortization Expenses - New Businesses	**11.6**	**1.2**	
Other Income	0.3	2.6	
EBIT	**23.7**	**50.1**	
Finance Cost	6.2	5.3	
Profit Before Tax	**17.5**	**44.8**	
Tax Expenses	3.5	14.9	
Profit After Tax (PAT)	**14.1**	**29.9**	
PAT Margins (%)	**6%**	**15%**	

Drag on reported PBT due to New Businesses :

- **Opex - Rs. 23 crs**
- **Depreciation – 12 crs**

Net Debt as on :

- 30^{th} Jun. 2026 **~Rs. 398 crs**
- 20^{th} Sept. **~Rs. 326 crs**

About Symbiotec Pharmalab

Symbiotec: R&D Driven Pharmaceutical and Biotech Company

SYMBIOTEC

Market Leadership

- **Global Leader** — *in Corticosteroid and Steroidal Hormone APIs*[1]
- **Global Leader** — *in Hydrocortisone, Testosterone, and Methylprednisolone*[1]
- **57%** — *Average Market Share in Top 5 Products*[2]

Three Interlinked Platforms

- **Organic Chemistry** — *API Products*
- **Biotechnology** — *API Products and CDMO Services*
- **Complex Injectables** — *Double Chamber Vials, Bags, Syringes and Pre-Filled Syringes*

Commitment to Compliance

- **115+** — *Successful Regulatory and Customer Inspections (Since FY24)*
- **Zero** — *Critical Observations from Global Regulators (Since FY24)*
- Regulatory Approvals Obtained

US FDA	EU GMP	WHO-GMP
KFDA	PMDA	ANVISA

Robust Financials

- **INR 8,69.1 Crs** — *Revenue (FY26)*
- **63.7%** — *Gross Margin % (FY26)*
- **INR 2,41 Crs[4] / 27.7%[4]** — *EBITDA / EBITDA Margin % (FY26)*

✓ **Only Company globally** having presence across the **top 10 corticosteroid & steroidal hormone APIs in FY26**

✓ Amongst the **few backward-integrated Indian and global manufacturers** capable of producing in-house corticosteroid and hormone precursors

✓ **Flexible, multi-scale, fully-invested and vertically integrated** manufacturing platform

✓ **One of the first generics to develop Double Chamber Vials** through backward integration[3]

✓ **Long-standing relationships** with global pharma majors: All top 5 customers with us for 10+ years

Source: F&S industry report, RHP; (1) In terms of volume in FY26; (2) Market share in terms of volume for top 5 products of the company in FY26 - Progesterones, Hydrocortisones, Testosterones, Betamethasones, and Methylprednisolones; (3) for Methylprednisolone Sodium Succinate injection and Hydrocortisone Sodium Succinate; (4) Excludes INR 8.99 crs exceptional item pertaining to non-recurring impact of new wage code, EBITDA after deducting the exceptional items (as reported in the RHP) is INR 23.2. crs

Our Ethos Shaping Our Evolution

SYMBIOTEC

1 **Proactive in embracing new technologies**

(E.g.: Biotransformation, Precision Fermentation, Double Chamber Platforms, Continuous Flow Chemistry)

2 **Drives incremental innovation through complex product launches**

(E.g.: One of the first generics players globally to produce DCVs[1],
One of the few companies globally to successfully develop a complex API[2])



1 **Consistently invested in scaling capacity and infrastructure**
(Capex: INR 806.9 crs[3])

2 **Compete effectively with larger global players and address expanding demand**

1 **Commitment to regulated market compliance**

(Zero critical observations from global regulators since FY24[3])

2 **Commitment to maintaining compliance requirements allows the company to serve leading pharma innovators & generics across highly regulated markets**

Source: RHP; (1) Double Chamber Vial for Methylprednisolone Sodium Succinate and Hydrocortisone Sodium Succinate; (2) with 82 US FDA mandated components despite the product's primary composition patents having expired several decades prior; (3) From FY24 to FY26

Symbiotec's Investment in Scale To Address Expanding Demand & Commitment to Compliance

SYMBIOTEC

Phase 1: 2004 to 2010	Phase 2: 2011 to 2020	Phase 3: 2021 to date
Building leadership in steroids and hormones	Scaling fermentation capabilities	Leveraging fermentation to expand horizons

Cumulative maximum capacity [1]

	2004	2010	2010	2013	2025	2025
DCV[2]						20 mn
Fermentation			20 KL	300 KL	700 KL	700 KL
Chemical Synthesis	92 MT	~585 MT	~585 MT	~585 MT	~585 MT	~585 MT

1995 – *Began Operations at Lab Scale*

	2004	2010	2010	2013	2025	2025	2026
	Commenced production at 1st API Plant at Rau	*Commenced production of steroid–hormones at SEZ, Pithampur*	*Commissioned biotech plant at SEZ, Pithampur (20KL)*	*Expansion of Biotech plant at SEZ, Pithampur (280KL)*	*Commissioned biomanufacturing Facility at Ujjain (400KL)*	*Commissioned DCV[2] facility at Mhow, Indore*	*New biologics facility (14KL) at Ujjain and trials in progress of continuous flow block at SEZ, Pithampur*
Gross Block[3]	INR 1,728 mn	INR 4,705 mn			INR 4,795 mn	INR 3,919 mn	
	Rau	*SEZ, Pithampur*			*Ujjain*	*Mhow*	

Approvals Obtained Since	US FDA	EU-GMP	WHO-GMP	KFDA	PMDA	ANVISA
	16 years	18 years	21 years	3 years	3 years	2 years

Source: F&S Industry report; (1) At company level; (2) DCV: Double Chamber Vials; (3) Gross Block of INR 1514.7 crs as on March 31, 2026 calculated as the sum of gross property, plant and equipment, capital work-in-progress, intangible assets, intangible assets under development and right-of-use assets

Vertically Integrated "Farm / Microbe to Pharmacy" Approach Driving Cost Efficiency and Enabling Expansion Across Adjacencies

SYMBIOTEC



Make vs Buy
Decision-Making Flexibility for KSMs of 80%+ product portfolio[3]

Reduced Dependence
On China for Intermediates

Cost Advantage
Through End-to-End Integration

Existing Fermentation Technology / Products — *Existing Manufacturing Infrastructure* — *Existing Client Relationships*

Source: F&S Industry report; Note: (1) Biologics facility is yet to be commissioned; (2) Double Chamber Vials, Double Chamber Syringes, Double Chamber Bags; (3) Products representing over 80% of revenue

What Differentiates Symbiotec?

SYMBIOTEC

1. Global Leadership in Corticosteroid and Steroidal-Hormone APIs
2. Ability to Leverage Science and Existing Competencies to Increase TAM and Deepen Intellectual Property-driven Offerings
3. Fully-Invested, Multi-scale, Vertically Integrated Manufacturing Platform with Clean Regulatory Track Record
4. Continuous Investment in R&D, with Leading Technological Capabilities Among Indian Peers
5. Seasoned Leadership Team Supported by Strong Pool of Experienced Management and Marquee Investors
6. Robust Financials With Strong Gross Margins, High Capital Efficiency and Cash Conversion

Source: RHP

1 Delivering End-to-End Solutions to Global Partners

SYMBIOTEC

A Supplying products to over 200 customers in over 40 countries



Exports 67%

+ indirect exports to regulated markets from domestic market

40+
Country Presence

50+
Domestic Customers

150+
Export Customers

EXPANDING ACCESS TO QUALITY PHARMACEUTICALS WORLDWIDE

B Retain & grow long-term relationships with broad customer base

2 out of Top 5
Customers are innovators

Revenues by vintage of relationships

Length of Relationship	1-3 Years	4-7 Years	Over 7 Years
% of FY26 Revenue	16%	7%	69%

Details of Top 5 Customers

Customers	Innovator / Generic	Length of Relationship	# of Products Supplied (2)
Customer 1	Innovator	10+ Years	4
Customer 2	Generic	10+ Years	7
Customer 3	Innovator	10+ Years	4
Customer 4	Generic	10+ Years	8
Customer 5	Generic	10+ Years	4

Low customer churn in corticosteroid and steroidal hormone APIs
due to manufacturing and regulatory complexity

Source: F&S Industry report; (1) RoW includes Asia (other than India) and Africa; (2) Refers to the number of products supplied in the year ended March 31, 2026

2.1 Leveraging Core Platforms and Existing Strengths To Expand Across Adjacencies and Deepen Intellectual Property-Driven Offerings Across Verticals (1/2)

SYMBIOTEC

Complex Injectables

Innovators Dominated Market

65-70% market share of innovators for DC vial products[1]

DCV Commands substantial price premium over conventional injectables due to key advantages over normal vials

One of the first generics globally to develop DCV through backward integration[2]

Symbiotec's Right to Win

In-house API supply	Distribution partnership	High entry barriers

- Product Sales
- Milestone Payments
- Profit / Revenue Share

Double Chamber Bags,
Double Chamber Syringes, Pre-Filled Syringes

Commercialization

Manufacturing

18-20mn Vial Capacity

Market Appeal

Offers a product presentation, which supports brand differentiation & end-user satisfaction.

Operational Convenience

Enhances workflow with ease-of-use, safety, and reliability in high-throughput environments.

Source: F&S Industry report; Note: (1) As of 31 December, 2025; (2) for Methylprednisolone Sodium Succinate injection and Hydrocortisone Sodium Succinate; (3) TAM for US in 2025

2.2 Leveraging Core Platforms and Existing Strengths To Expand Across Adjacencies and Deepen Intellectual Property-Driven Offerings Across Verticals (2/2)

SYMBIOTEC

Biotech - CDMO Services

The India Advantage

30-50%

Lower Set-up and Commissioning Cost

Affordable RM Access

Driven by Agriculture-linked Indian economy

Low Operating Cost

Of Utilities, Labour and Compliance

Ecosystem

Growing CDMO Ecosystem

One of India's largest industrial-scale fermentation capacities

Symbiotec's Right to Win

Successfully demonstrated technology at 100 KL scale	Multi-scale flexible mfg.	JV agreement in place

Service Income ✓ (green)

Profit / Revenue Share ✓ (yellow)

Potential Future Offerings: Food, nutraceuticals, biologics & industrial biotech CDMO

Commercialization

Bio-Pharma CDMO

- ✓ **Insulin Drug Substance** (already entered a five years take-or-pay arrangement)
- ✓ **Classic fermentation-based APIs**

Bio-manufacturing CDMO

- ✓ **Alternate proteins** (already entered a ten-year take-or-pay contract with a United States company and a term sheet with a European Company)

✓ (green) Customer relationship established and revenue generated
✓ (yellow) Customer relationship established; revenue not generated

Source: F&S Industry report; Note: (1) TAM for select successes in each adjacency for 2025

3 Fully-Invested, Multi-scale, Vertically Integrated Manufacturing Platform

SYMBIOTEC

Operating leverage and future earnings potential from investments in infrastructure



Flexible multi-scale fermentation capabilities, backed by signed customer contracts

Fermenter size at Symbiotec from

5KL to 100KL in existence

Among few Indian players to possess **Multi-Scale Fermenters**	Allowing to efficiently produce **high-volume and low-volume fermentation products**	Scale diversity enables **flexible CDMO services**	Biologics capacity (dedicated 14 KL capacity) **to cater to GLP-1 & Insulin**

Scaled manufacturing infrastructure

Rau, Indore
Capacity
92MT
API per annum

SEZ, Pithampur
Capacity
493MT API per annum +
300KL fermentation volume

Ujjain
Capacity
400KL
Fermentation volume

Mhow, Indore
Capacity
18-20 mn
Vials (Injectables) per annum

Source: F&S Industry report

Science Based Platform with Continuous Investment in R&D

SYMBIOTEC

Focused innovation: R&D efforts across three interlinked platforms

156 R&D Employees[1]

Organic Chemistry

86+ *Scientists*[1]

Capabilities:

- ✓ Hydrogenation
- ✓ Aromatisation
- ✓ Cryogenic / Grignard chemistry
- ✓ Photochemistry
- ✓ Continuous Flow Chemistry

Equipment:

- ✓ High/Ultra Performance Liquid Chromatography
- ✓ Chromatography systems
- ✓ Liquid chromatography–mass spectrometry
- ✓ Inductively coupled plasma mass spectrometry

Biotechnology

39+ *Scientists*[1]

Capabilities:

- ✓ Biotransformation
- ✓ Biosynthesis
- ✓ Precision fermentation
- ✓ Strain Improvement
- ✓ Downstream purification including high pressure column chromatography

Equipment:

- ✓ Real-time polymerase chain reaction systems
- ✓ Nucleic acid extractors
- ✓ Preparatory scale high-performance liquid chromatography systems

Complex Injectables

14 *Scientists*[1]

Capabilities:

- ✓ Active freeze drying (a lyophilisation technique)
- ✓ Double chamber drug-device platforms
- ✓ Packaging solutions

Equipment:

- ✓ Double Chamber Vial (DCV) filling machine
- ✓ Lyophilizer
- ✓ Filteration vessel
- ✓ X-ray inspection machine
- ✓ Labelling machine

Continuous investment in R&D…

R&D spend as % of sales



…leading to R&D breakthroughs

Up to 400 *synthesis Steps validated under cGMP efficiently*

One of the First Generics *to develop Double Chamber Vials through backward integration*[2]

Source: F&S Industry report, RHP; Note: (1) As of 31 Mar 2026 (2) for Methylprednisolone Sodium Succinate injection and Hydrocortisone Sodium Succinate

5 Seasoned Leadership Supported by Experienced Management and Marquee Investors

SYMBIOTEC

Anil Satwani
Promoter, Chairman and Managing Director,
Over 30 years of experience in the pharmaceutical sector

Sushil Satwani
Promoter, Director – Commercial
23+ years of experience

Kashish Satwani
Promoter, President – HR
23+ years of experience

Second Generation

Krishna Satwani

Arjun Satwani

Raghavender Ramachandran
Chief Financial Officer

Anant Achyut Deshpande
President – Operations

Parakalan Srinivasan
Senior Vice President, Operations & Project - Formulations

Raman Prasad
Vice President – R&D and Manufacturing, Biotech

Kapil Mishra
Strategy Head – Chairman and MD's Office

Nishikant Digambar Ghadge
Vice President – R&D and Manufacturing, Chemistry

Dharm Shanker Pandey
Vice President, Quality Assurance

Vijay Bajpai
Chief Human Resource Officer

Suman Podder
Associate Vice President, Regulatory Affairs

Sandeep Patil
Chief Technology Officer in the Systems (Information Technology) Department

Saurabh Sahu
Associate Vice President – R&D, Formulations

Shubham Saboo
General Manager – Chairman and MD's Office

6.1 Multiple Building Blocks in Place to Fuel Growth Strategies (1/2)

SYMBIOTEC

1 Expand Product Portfolio Across Steroidal Hormones

- ✓ **Corticosteroid and steroidal hormone API**
  - ✓ Expand across product categories, therapeutic areas, and global markets
- ✓ **Classical fermentation-based APIs**
  - ✓ Scale up of new launches such as Mupirocin and Serratiopeptidase, among others
  - ✓ Additional high-value, low-volume APIs in niche therapeutic areas
- ✓ **Differentiated APIs enabled by synthetic biology platforms**
- ✓ **High-value complex APIs** incl. steroidal derivatives such as vitamin D3

2 Build on Fermentation Capabilities and Expand Biotech Offerings

- ✓ **Ujjain facility has been commissioned with R&D and pilot-scale operations started** to enable **large volume fermentation manufacturing** for:
  - API products
  - CDMO services for industrial biotechnology products such as alternate proteins, enzymes
  - Backward integration for corticosteroid and steroidal hormone APIs
- ✓ **Expand production of high-value biologics such as GLP-1 analogues and insulin** at the proposed biologics facility in Ujjain

3 Commercialize Complex Injectables Through Differentiated DDCs

- ✓ **Under process of forward integrating into complex injectables**
  - Commercialize two double chamber vial (DCV) products
  - Pipeline of additional double chamber products under the 505(b)(2) pathway to accelerate market entry
- ✓ **Expand into Double chamber bags** (proof of concept established; currently in stability testing phase)

Source: RHP

6.2 Multiple Building Blocks in Place to Fuel Growth Strategies (2/2)

SYMBIOTEC

4 Scale Up Diverse Biotech - CDMO Offerings Based on Three Interlinked Platforms

- ✓ Establish a **comprehensive, sector-agnostic Biotech - CDMO platform**
- ✓ **Operationalize the Ujjain facility as a base for industrial biotech CDMO opportunities**, including precision fermentation, nutraceuticals, and alternate proteins
- ✓ **Leveraging capabilities in synthetic biology**, strain development, and large-scale microbial fermentation
- ✓ **Deepen engagements with existing CDMO clients as well as pursue new global opportunities** (US, EU, India) to scale the breadth and depth of CDMO offerings in biologics and fermentation-based API

5 Continue to Invest in New Technologies and R&D

- ✓ Sustain and expand innovation-driven business model by **consistently investing in technologies and strengthening the R&D infrastructure**
- ✓ **Reduce manufacturing costs** and **improve process efficiencies** for existing products
- ✓ Leverage scientific expertise and integrated capabilities to **address unmet global market opportunities**
- ✓ **Continue to invest in automation, digitalization, and AI-driven process optimization**

6 Partner With Large Companies for Difficult-to-execute Projects

- ✓ Deepen strategic collaborations with global and regional pharmaceutical companies to **co-develop and commercialize complex, high-barrier projects**
- ✓ Structuring **collaborations around shared economics** of risks and economic rewards
- ✓ **Accelerate adoption of differentiated, innovative products** by pursuing CDMO contracts and collaborations with partners in areas such as complex injectables and industrial biotech products

Source: RHP

Annexures : Historical Financial Statements

Historical Profit & Loss Statement

SYMBIOTEC

Particular (Rs. in Crs)	FY26	FY25	FY24
Revenue from Operations	869.1	751.6	716.2
Cost of Goods Sold	315.5	297.4	321.0
Gross Profit	553.7	454.2	395.2
Gross Margins (%)	63.7%	60.4%	55.2%
Employees Cost	154.3	122.3	104.1
Other Expenses	161.5	130.0	119.8
Reported EBITDA	237.9	201.8	171.3
Reported EBITDA Margin (%)	27.4%	26.9%	23.9%
Depreciation & Amortization Expenses	53.3	43.1	38.8
Other Income	3.1	4.4	7.1
EBIT	187.7	163.2	139.6
EBIT Margin	22%	22%	19%
Finance Cost	25.3	16.0	7.2
Exceptional Item Gain / (Loss)*	-9.0	0.0	0.0
Profit before share of profit/loss from JVs	153.4	147.1	132.3
Share of Profit/(loss) from JVs	0.0	-0.2	-1.4
Profit Before Tax	153.4	147.0	131.0
Tax Expenses	43.5	50.2	30.9
Profit After Tax	109.9	96.8	100.1
PAT Margins (%)	12.6%	12.9%	14.0%

*Impact of New wages code on Gratuity & Leave encashment

Consolidated

Historical Balance Sheet

SYMBIOTEC

Particular (Rs. in Crs)	FY26	FY25	FY24
Assets			
Property, plant and equipment	1084.4	401.5	411.2
Capital work-in-progress	64.5	568.2	208.3
Investment properties	35.9	36.5	37.0
Intangible assets	-	-	0.2
Investments accounted for using equity method	-	-	3.5
Financial assets	13.4	6.6	5.0
Income tax assets (net)	0.0	0.9	6.1
Other non-current assets	97.0	73.1	115.2
Non-current Assets	**1295.2**	**1086.8**	**786.6**
Inventories	236.9	261.5	335.8
Trade receivables	197.6	175.7	125.7
Cash and cash equivalents	10.0	26.4	7.5
Bank Balances other than cash and cash equivalents	0.1	0.1	0.1
Other financial assets	27.2	15.8	17.7
Other current assets	13.7	13.4	21.5
Current Assets	**485.5**	**492.9**	**508.2**
Total Assets	**1780.8**	**1579.7**	**1294.8**

Particular (Rs. in Crs)	FY26	FY25	FY24
Equity and Liabilities			
Total Equity	**1149.6**	**814.7**	**714.8**
Borrowings	68.4	253.0	195.2
Lease liabilities	2.1	2.6	2.8
Other financial liabilities	5.8	1.5	-
Provisions	21.6	13.3	10.7
Deferred tax liabilities (net)	5.8	22.0	19.9
Non-current Liabilities	**103.6**	**292.3**	**228.7**
Borrowings	319.5	287.9	52.0
Lease liabilities	1.0	0.9	0.5
Trade payables	138.3	88.5	227.6
Other financial liabilities	34.4	40.4	20.2
Other current liabilities	19.7	39.8	44.2
Provisions	6.6	4.1	3.6
Current tax liabilities (net)	7.9	11.0	3.0
Current Liabilities	**527.6**	**472.6**	**351.2**
Total Equity and Liabilities	**1780.8**	**1579.7**	**1294.8**

Consolidated

Historical Cash Flow Statement

SYMBIOTEC

Particulars (Rs. in Crs)	FY26	FY25	FY24
Net Profit Before Tax	**153.4**	**147.0**	**131.0**
Adjustments for: Non -Cash Items / Other Investment or Financial Items	85.4	61.9	41.1
Operating profit before working capital changes	**238.8**	**208.9**	**172.1**
Changes in working capital	-2.5	-126.8	49.7
Cash generated from Operations	**236.3**	**82.1**	**221.8**
Direct taxes paid (net of refund)	-61.7	-34.8	-34.3
Net Cash from Operating Activities	**174.6**	**47.3**	**187.5**
Net Cash from Investing Activities	**-226.9**	**-306.5**	**-206.4**
Net Cash from Financing Activities	**36.0**	**278.2**	**21.8**
Net Increase/(Decrease) in Cash and Cash equivalents	**-16.4**	**18.9**	**2.9**
Add: Cash & Cash equivalents at the beginning of the period	26.4	7.5	4.6
Cash & Cash equivalents at the end of the period	**10.0**	**26.4**	**7.5**

Consolidated

Historical Financial Highlights

SYMBIOTEC

Revenue (Rs. in Crs)



EBITDA (Rs. in Crs)



PAT (Rs. in Crs)



Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



Consolidated

Financial Ratios

SYMBIOTEC

Adjusted ROCE[1]



OCF To EBITDA[2] (x)



Debt to Equity (x)



GFTAR[3] (x)



(1)Adjusted ROCE after excluding the Capital Employed attributable to Knovea Pharmaceutical Private Limited and Symbiotec Zenfold Private Limited. Similarly, EBIT for the period/year is adjusted by excluding the profit/(loss) of Knovea Pharmaceutical and Symbiotec Zenfold Private Limited to arrive at a normalised operating performance measure ; (2)OCF refers to net cash flow from operating activities ; (3) Gross fixed asset turnover = Revenue from operations / Gross fixed assets

Consolidated

Thank You

For further Information, please connect :

Company:

SYMBIOTEC

Symbiotec Pharmalab Ltd.
CIN – U24232MP2002PLC015293

investorrelations@symbiotec.com

Investor Relations Advisor:

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Mr. Sagar Shroff / Mr. Prabjeet Singh Tank
sagar.shroff@sgapl.net / prabjeet.singh@sgapl.net
+91 98205 19303 / +91 81690 49325
www.sgapl.net